Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease... Show more
Industry Biotechnology
A.I.dvisor indicates that over the last year, CLDI has been loosely correlated with TBPH. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDI jumps, then TBPH could also see price increases.
| Ticker / NAME | Correlation To CLDI | 1D Price Change % | ||
|---|---|---|---|---|
| CLDI | 100% | +0.93% | ||
| TBPH - CLDI | 46% Loosely correlated | N/A | ||
| PROK - CLDI | 32% Poorly correlated | +3.01% | ||
| BNTX - CLDI | 29% Poorly correlated | -1.48% | ||
| RYTM - CLDI | 29% Poorly correlated | -1.90% | ||
| MBIO - CLDI | 29% Poorly correlated | +0.97% | ||
More | ||||
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CLDI declined for three days, in 223 of 240 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on September 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLDI as a result. In 55 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Aroon Indicator for CLDI entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLDI's RSI Oscillator exited the oversold zone, 30 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for CLDI just turned positive on September 24, 2026. Looking at past instances where CLDI's MACD turned positive, the stock continued to rise in 25 of 44 cases over the following month. The odds of a continued upward trend are 57%.
Following a +3.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDI advanced for three days, in 67 of 133 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
CLDI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.883) is normal, around the industry mean (26.780). P/E Ratio (0.752) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. CLDI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.